Changes to the Code
S. 4698 · Right to Try for Individualized Treatments Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 360bbb–0a Investigational drugs for use by eligible patients
13 changes the bill asks for here, 13 carried out
- Carried out:
by amending paragraph (1) to read as follows:
(1) the term “eligible patient” means— (A) in the case of a patient requesting an eligible investigational drug, a patient who has— (i) been diagnosed with a life-threatening disease or condition (as defined in section 312.81 of title 21, Code of Federal Regulations (or any …
- Carried out:
in paragraph (2)(D), by striking
and
at the end; - Carried out:
in paragraph (3), by striking the period at the end and inserting a semicolon
;
and - Carried out:
by adding at the end the following:
(4) the term “eligible health care facility” means a health care facility that is operating under the Federal assurance for protection of human subjects pursuant to section 491(a) of the Public Health Service Act; (5) the term “investigational individualized medical treatment” …
- Carried out:
by redesignating subsections (b) through (d) as subsections (c) through (e), respectively; and
- Carried out:
by inserting after subsection (a) the following:
(b) Eligibility for investigational individualized medical treatment.— A manufacturer of an investigational individualized medical treatment that is in compliance with all applicable Federal assurance laws and regulations and is operating within an eligible health care facility …
- Carried out:
by inserting
and investigational individualized medical treatments
afterEligible investigational drugs
; - Carried out:
by inserting
or investigational individualized medical treatment
aftersuch eligible investigational drug
; - Carried out:
by inserting
or investigational individualized medical treatment
afteran eligible investigational drug
; and - Carried out:
by inserting
or investigational individualized medical treatments
afterinvestigational drugs
. - Carried out:
in the section heading, by inserting
and investigational individualized medical treatments
afterdrugs
; and - Carried out:
in subparagraph (A), by striking
subsection (c)(1)(A)
and insertingsubsection (d)(1)(A)
; and - Carried out:
in subparagraph (B), by striking
subsection (c)(1)(B)
and insertingsubsection (d)(1)(B)
.
§ 360bbb–0a(a)
§ 360bbb–0a. Investigational drugs [inserted: and investigational individualized medical treatments ]for use by eligible patients
(a) Definitions For purposes of this section—
(1) the term “eligible patient” means[struck: a patient]—
(A) [inserted: in the case of a patient requesting an eligible investigational drug, a patient who has—]
(i) [inserted: been diagnosed with a life-threatening disease or condition (as defined in section 312.81 of title 21, Code of Federal Regulations (or any successor regulations));]
(ii) [inserted: exhausted approved treatment options and is unable to participate in a clinical trial involving the eligible investigational drug, as certified by a physician, who—]
(I) [inserted: is in good standing with the physician’s licensing organization or board; and]
(II) [inserted: will not be compensated directly by the manufacturer of such drug for so certifying; and]
(iii) [inserted: provided to the treating physician written informed consent regarding the eligible investigational drug, or, as applicable, on whose behalf a legally authorized representative of the patient has provided such consent; or]
[struck: who has been diagnosed with a life-threatening disease or condition (as defined in section 312.81 of title 21, Code of Federal Regulations (or any successor regulations));]
(B) [struck: who][inserted: in] [struck: has][inserted: the] [struck: exhausted][inserted: case] [struck: approved][inserted: of] [struck: treatment options and is unable to participate in ]a [struck: clinical][inserted: patient] [struck: trial][inserted: requesting] [struck: involving][inserted: an] [struck: the][inserted: investigational] [struck: eligible][inserted: individualized] [struck: investigational][inserted: medical] [struck: drug][inserted: treatment], [struck: as certified by ]a [struck: physician,][inserted: patient] who[inserted: has]—
(i) [struck: is][inserted: been] [inserted: diagnosed with a life-threatening disease or condition or severely debilitating illness (as such terms are defined ]in [struck: good][inserted: section] [struck: standing][inserted: 312.81] [struck: with][inserted: of] [struck: the][inserted: title] [struck: physician’s][inserted: 21,] [struck: licensing][inserted: Code] [struck: organization][inserted: of] [inserted: Federal Regulations (]or [struck: board;][inserted: any] [struck: and][inserted: successor regulations));]
(ii) [inserted: considered approved treatment options, as certified by a physician, who—]
(I) [inserted: is in good standing with the physician’s licensing organization or board;]
(II) [inserted: will not be compensated directly by the manufacturer of such treatment for so certifying; and]
(III) [inserted: attests to the patient’s life-threatening disease or condition or severely debilitating illness; and]
(iii) [inserted: provided to the treating physician—]
(I) [inserted: written informed consent regarding the eligible investigational drug or, as applicable, on whose behalf a legally authorized representative of the patient has provided such consent; or]
(II) [inserted: as applicable, additional informed consent, regarding the investigational individualized medical treatment, or, as applicable, on whose behalf a legally authorized representative of the patient has provided such consent;]
[struck: will not be compensated directly by the manufacturer for so certifying; and]
[struck: (C)] [struck: who has provided to the treating physician written informed consent regarding the eligible investigational drug, or, as applicable, on whose behalf a legally authorized representative of the patient has provided such consent;]
(2) the term “eligible investigational drug” means an investigational drug (as such term is used in section 360bbb of this title)—
(A) for which a Phase 1 clinical trial has been completed;
§ 360bbb–0a(a)–(e)
(a)(2)(B)–(C) unchanged ·
(II) is the subject of an active investigational new drug application under section 355(i) of this title or section 351(a)(3) of the Public Health Service Act [42 U.S.C. 262(a)(3)], as applicable; and
(D) the active development or production of which is ongoing and has not been discontinued by the manufacturer or placed on clinical hold under section 355(i) of this title;[struck: and]
(3) the term “phase 1 trial” means a phase 1 clinical investigation of a drug as described in section 312.21 of title 21, Code of Federal Regulations (or any successor regulations)[struck: .][inserted: ;]
(4) [inserted: the term “eligible health care facility” means a health care facility that is operating under the Federal assurance for protection of human subjects pursuant to section 491(a) of the Public Health Service Act;]
(5) [inserted: the term “investigational individualized medical treatment” means a drug or biological product for the patient based on an analysis of the patient’s unique genomic profile, including their genomic sequence, human chromosomes, deoxyribonucleic acid, genes, gene products (such as enzymes and other types of proteins), or metabolites; and]
(6) [inserted: the term “additional informed consent” means consent attested to in writing by the patient’s physician and a witness for an investigational individualized medical treatment that includes—]
(A) [inserted: an explanation of the currently approved treatments for the patient’s disease or condition;]
(B) [inserted: the patient’s attestation that the patient concurs with the assessment of their physician that all currently approved and conventionally recognized treatments are unlikely to prolong or improve their life;]
(C) [inserted: clear identification of the specific proposed investigational individualized medical treatment the patient’s physician recommends; and]
(D) [inserted: a description, based on the physician’s knowledge of the proposed treatment and the patient’s disease, of the potential outcomes of the treatment.]
(b) [inserted: Eligibility for investigational individualized medical treatment.—] [inserted: A manufacturer of an investigational individualized medical treatment that is in compliance with all applicable Federal assurance laws and regulations and is operating within an eligible health care facility may make available such investigational individualized medical treatment, and an eligible patient may request access to such treatment from the eligible health care facility or manufacturer of such treatment, consistent with the requirements of this section. A manufacturer of an investigational individualized medical treatment is not required to make available such treatment to any patient.]
[struck: (b)] [inserted: (c)] Exemptions Eligible investigational drugs [inserted: or investigational individualized medical treatments and investigational individualized medical treatments ]provided to eligible patients in compliance with this section are exempt from sections 352(f), 353(b)(4), 355(a), and 355(i) of this title, section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)], and parts 50, 56, and 312 of title 21, Code of Federal Regulations (or any successor regulations), provided that the sponsor of such eligible investigational drug or [inserted: investigational individualized medical treatment or ]any person who manufactures, distributes, prescribes, dispenses, introduces or delivers for introduction into interstate commerce, or provides to an eligible patient an eligible investigational drug [inserted: or investigational individualized medical treatment ]pursuant to this section is in compliance with the applicable requirements set forth in sections 312.6, 312.7, and 312.8(d)(1) of title 21, Code of Federal Regulations (or any successor regulations) that apply to investigational drugs.
[struck: (c)] [inserted: (d)] Use of clinical outcomes
(1) In general Notwithstanding any other provision of this chapter, the Public Health Service Act [42 U.S.C. 201 et seq.], or any other provision of Federal law, the Secretary may not use a clinical outcome associated with the use of an eligible investigational drug pursuant to this section to delay or adversely affect the review or approval of such drug under section 355 of this title or section 351 of the Public Health Service Act [42 U.S.C. 262] unless—
(A) the Secretary makes a determination, in accordance with paragraph (2), that use of such clinical outcome is critical to determining the safety of the eligible investigational drug; or
(B) the sponsor requests use of such outcomes.
(2) Limitation If the Secretary makes a determination under paragraph (1)(A), the Secretary shall provide written notice of such determination to the sponsor, including a public health justification for such determination, and such notice shall be made part of the administrative record. Such determination shall not be delegated below the director of the agency center that is charged with the premarket review of the eligible investigational drug.
[struck: (d)] [inserted: (e)] Reporting
(1) In general The manufacturer or sponsor of an eligible investigational drug shall submit to the Secretary an annual summary of any use of such drug under this section. The summary shall include the number of doses supplied, the number of patients treated, the uses for which the drug was made available, and any known serious adverse events. The Secretary shall specify by regulation the deadline of submission of such annual summary and may amend section 312.33 of title 21, Code of Federal Regulations (or any successor regulations) to require the submission of such annual summary in conjunction with the annual report for an applicable investigational new drug application for such drug.
(2) Posting of information The Secretary shall post an annual summary report of the use of this section on the internet website of the Food and Drug Administration, including the number of drugs for which clinical outcomes associated with the use of an eligible investigational drug pursuant to this section was—
(A) used in accordance with subsection ([struck: c][inserted: d])(1)(A);
(B) used in accordance with subsection ([struck: c][inserted: d])(1)(B); and
(C) not used in the review of an application under section 355 of this title or section 351 of the Public Health Service Act [42 U.S.C. 262].